Covid-19 vaccine makers told Congress on Feb. 23 that U.S. supplies should surge in the coming weeks due to manufacturing expansions and new vaccine authorizations.

Drug developer Novavax Inc. completed enrolling 30,000 volunteers in a late-stage study of the company’s Covid-19 vaccine in the United States and Mexico.

Novavax announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to provide 1.1 billion doses of the company’s Covid-19 vaccine candidate NVX-CoV2373 for the COVAX Facility.

As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.

Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.

The results are in from Johnson & Johnso’s global Phase III ENSEMBLE clinical trial, and the company’s single-shot vaccine is 66% effective overall in preventing moderate-to-severe Covid-19, 28 days after vaccination.

Novavax Inc. expects to produce up to 150 million Covid-19 vaccine doses monthly by May or June, the company’s chief executive told Reuters, a day after reporting interim data that showed its shot to be 89% effective in a UK trial.

Novavax Inc. said the company’s coronavirus vaccine was 89.3% effective in preventing Covid-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis.

Merck is stopping development of the company’s two Covid-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.

Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.